Jeffrey Hargis, MD
Hematology & Oncology · Louisville, KYNPI 1437122454
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $332,325 of the $449,831 with a category attached, or 73.9%. 16 manufacturers reported payments, led by AstraZeneca at 25.2% of the total. Among hematology & oncology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $1277.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$113K
- Gilead$101K
- Daiichi Sankyo Inc.$84K
- Stemline Therapeutics Inc.$47K
- Seagen Inc.$29K
- Pfizer$22K
- plus $53K from 10 others
Across 161 payments — averaging $5145.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$276K
- Novartis$223K
- Stemline Therapeutics Inc.$91K
- Radius Health, Inc.$86K
- AstraZeneca$61K
- Genentech, Inc.$32K
- plus $60K from 4 others
What the payments were for
- Consulting fees$61,50714%
- Speaking & faculty fees$332,32574%
- Travel & lodging$46,91210%
- Food & beverage$7,7332%
- Education$2560%
- Other$1,0980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 65 | $113,381 |
| Gilead | 86 | $101,376 |
| Daiichi Sankyo Inc. | 65 | $83,816 |
| Stemline Therapeutics Inc. | 32 | $46,728 |
| Seagen Inc. | 22 | $29,349 |
| Pfizer | 16 | $21,900 |
| Genentech USA, Inc. | 17 | $20,061 |
| Merck | 17 | $16,283 |
| Novartis | 21 | $8,011 |
| Puma Biotechnology, Inc. | 3 | $4,317 |
| Immunomedics, Inc. | 2 | $2,425 |
| Eisai Inc. | 2 | $1,745 |
| Covis Pharma GmbH | 1 | $200 |
| Amgen | 1 | $100 |
| Macrogenics, Inc. | 1 | $98 |
| Lilly USA, LLC | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$449,831 in reported general payments places this provider in the 95th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fentanyl | 33 | $2,860 |
| Anastrozole | 129 | $2,684 |
| Letrozole | 118 | $2,351 |
| Tamoxifen Citrate | 42 | $923 |
| Oxycodone Hcl | 21 | $648 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $434 |
| Dexamethasone | 28 | $254 |
| Ondansetron Hcl | 29 | $197 |
| Promethazine Hcl | 19 | $97 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Louisville
- Vivek SharmaLouisville$647K
- Goetz KloeckerLouisville$584K
- Mohamed HegaziLouisville$380K
- Khuda KhanLouisville$359K
- Jaspreet GrewalLouisville$280K
- Laila AgrawalLouisville$95K
- Brian DongLouisville$31K
- Rohit KumarLouisville$31K
- Vikas SinghLouisville$28K
- Adam LyeLouisville$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.